Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00734188 | Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma | PHASE1 | COMPLETED | 21 | — | — | Jan 1, 2009 | Jun 1, 2010 | Jul 14, 2011 | 1 | Israel |
| Name | Type | Description |
|---|---|---|
| PTI-6D2 | DRUG | monoclonal antibody |
Inclusion Criteria: * Patients must have histologically or clinically confirmed malignant melanoma of one of the following stages (according to 2002 American Joint Committee on Cancer criteria: Appendix C): Unresectable Stage III disease or Stage IV disease * Patients must have measurable disease a...